Human Clinical Trial Plan for Original BioMedicals B01 Cyanide Compound Drug (Patent: Composition for Upper Respiratory Tract Administration and Method) Has Been Approved by the Joint IRB of Taipei Medical University and Its Affiliated Hospital.
Important News
1.Our company has received notification from the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospital that our application for the project titled “First-in-Human Study of Inhalation of a Fixed-Ratio Combination of Vitamin B12 (Hydroxocobalamin, OHCbl) and Iron Chelator (Deferoxamine Mesylate, DFO) Using a Drug Nebulizer in Healthy Adults” has been approved.
2.This project, part of our company’s B01 cyanide compound drug program (patent title: “Composition for Upper Respiratory Drug Administration and Method of Administration”), involves human inhalation through a nebulizer approved by the Ministry of Health and Welfare （衛部醫器陸輸字第001782號）.
3.The purpose of this study is to evaluate the feasibility, safety, and human tolerability of an inhaled fixed-ratio combination of Hydroxocobalamin (OHCbl) and Deferoxamine Mesylate (DFO) for protective use in fire smoke exposure scenarios, serving as the foundation for subsequent clinical development and emergency protection applications.
